AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 256: R1318-R1324, 1989;
0363-6119/89 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunlap, C. E.
Right arrow Articles by Valego, N. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunlap, C. E., 3rd
Right arrow Articles by Valego, N. K.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 256, Issue 6 1318-R1324, Copyright © 1989 by American Physiological Society

ARTICLES

Cardiovascular effects of dynorphin A-(1-13) and arginine vasopressin in fetal lambs

C. E. Dunlap 3rd and N. K. Valego
Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.

The cardiovascular effects of the kappa-opioid receptor agonist, dynorphin A-(1-13) (D13), were compared with those of arginine vasopressin (AVP) in intact and bilaterally vagotomized (VGX) fetal lambs. Intravenous injection of AVP (114 ng/kg) produced a significant rise in mean arterial pressure (MAP) lasting 15-20 min in both intact and VGX lambs. AVP produced a bradycardia in intact fetuses concurrently with the MAP response and had no effect on heart rate (HR) in VGX fetuses. D13 (500 micrograms/kg) also produced significant increases in MAP in intact and VGX fetuses that lasted 45-60 min. D13 produced a bradycardia in intact fetal lambs but, unlike AVP, significantly increased HR in VGX fetuses. HR responses to D13 had time courses similar to MAP responses in both intact and VGX fetal lambs. Pretreatment with a vasopressin V1-receptor antagonist significantly attenuated pressor responses to AVP in both treatment groups and to D13 in intact fetuses and abolished the D13 pressor response in VGX fetuses. The antagonist also completely blocked HR responses to AVP in intact and to D13 in VGX fetuses and attenuated the D13 HR response in intact fetuses. Therefore the effects of D13 on ovine fetal cardiovascular function appear to be mediated in part through AVP pathways. D13 also appears to have a positive chronotropic effect on the heart that is normally masked by inhibitory vagal activity.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
C. C. Taylor, D. Wu, Y. Soong, J. S. Yee, and H. H. Szeto
Dynorphin A1-13 Stimulates Ovine Fetal Pituitary-Adrenal Function through a Novel Nonopioid Mechanism
J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 416 - 421.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online